Compare Duolingo Inc (DUOL) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs Davita Inc — how do they compare? Duolingo Inc trades at $151 (market cap $7.10B), while Davita Inc trades at $175.04 (market cap $11.28B). The key difference: Davita Inc is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Davita Inc for 113 Days on average.
| DUOL | DVA | |
|---|---|---|
Market Cap | $7.10B | $11.28B |
Volume | 922,471 | 650,294 |
Sector | Technology | Health |
52-Week High | $341.08 | $240.96 |
52-Week Low | $90.03 | $103.87 |
Typical Hold Time | 137 Days | 113 Days |
Enterprise Value | $5.87B | $24.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DUOL trades at $151.72, up 2.42% today, with a bullish technical outlook and strong support near $149. The company reported robust fundamentals, with Q2 2026 EPS beating expectations at $0.66 versus $0.604, and revenue growth accelerating to $1.04 billion in 2025. Operating cash flow surged to $387.82 million, reflecting strong operational efficiency.
The stock presents a compelling growth story with high net margins of 35.87% and consistent earnings beats, though valuation multiples like EV/EBITDA of 33.96 suggest premium pricing. Key risks include insider selling and competitive pressures in edtech. Analyst consensus is mixed with a $140.63 price target, indicating cautious optimism amid near-term volatility.
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
